The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Restless Legs Syndrome Market Research Report 2025
Synopsis
Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
The global Restless Legs Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report aims to provide a comprehensive presentation of the global market for Restless Legs Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Restless Legs Syndrome.
Report Scope
The Restless Legs Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Restless Legs Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Restless Legs Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals
Segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Segment by Application
Below 35 Years Old
From 35 to 50 Years Old
Above 50 Years Old
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Restless Legs Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
The global Restless Legs Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report aims to provide a comprehensive presentation of the global market for Restless Legs Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Restless Legs Syndrome.
Report Scope
The Restless Legs Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Restless Legs Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Restless Legs Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals
Segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Segment by Application
Below 35 Years Old
From 35 to 50 Years Old
Above 50 Years Old
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Restless Legs Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Restless Legs Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pharmacological Therapy
1.2.3 Non-Pharmacological Therapy
1.3 Market by Application
1.3.1 Global Restless Legs Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Below 35 Years Old
1.3.3 From 35 to 50 Years Old
1.3.4 Above 50 Years Old
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Restless Legs Syndrome Market Perspective (2019-2030)
2.2 Restless Legs Syndrome Growth Trends by Region
2.2.1 Global Restless Legs Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Restless Legs Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Restless Legs Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Restless Legs Syndrome Market Dynamics
2.3.1 Restless Legs Syndrome Industry Trends
2.3.2 Restless Legs Syndrome Market Drivers
2.3.3 Restless Legs Syndrome Market Challenges
2.3.4 Restless Legs Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Restless Legs Syndrome Players by Revenue
3.1.1 Global Top Restless Legs Syndrome Players by Revenue (2019-2024)
3.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Restless Legs Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Restless Legs Syndrome Revenue
3.4 Global Restless Legs Syndrome Market Concentration Ratio
3.4.1 Global Restless Legs Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Restless Legs Syndrome Revenue in 2023
3.5 Restless Legs Syndrome Key Players Head office and Area Served
3.6 Key Players Restless Legs Syndrome Product Solution and Service
3.7 Date of Enter into Restless Legs Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Restless Legs Syndrome Breakdown Data by Type
4.1 Global Restless Legs Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Restless Legs Syndrome Forecasted Market Size by Type (2025-2030)
5 Restless Legs Syndrome Breakdown Data by Application
5.1 Global Restless Legs Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Restless Legs Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Restless Legs Syndrome Market Size (2019-2030)
6.2 North America Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Restless Legs Syndrome Market Size by Country (2019-2024)
6.4 North America Restless Legs Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Restless Legs Syndrome Market Size (2019-2030)
7.2 Europe Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Restless Legs Syndrome Market Size by Country (2019-2024)
7.4 Europe Restless Legs Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Restless Legs Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Restless Legs Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Restless Legs Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Restless Legs Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Restless Legs Syndrome Market Size (2019-2030)
9.2 Latin America Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Restless Legs Syndrome Market Size by Country (2019-2024)
9.4 Latin America Restless Legs Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Restless Legs Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Restless Legs Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Detail
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2019-2024)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 UCB SA
11.2.1 UCB SA Company Detail
11.2.2 UCB SA Business Overview
11.2.3 UCB SA Restless Legs Syndrome Introduction
11.2.4 UCB SA Revenue in Restless Legs Syndrome Business (2019-2024)
11.2.5 UCB SA Recent Development
11.3 Astellas
11.3.1 Astellas Company Detail
11.3.2 Astellas Business Overview
11.3.3 Astellas Restless Legs Syndrome Introduction
11.3.4 Astellas Revenue in Restless Legs Syndrome Business (2019-2024)
11.3.5 Astellas Recent Development
11.4 Arbor Pharmaceuticals
11.4.1 Arbor Pharmaceuticals Company Detail
11.4.2 Arbor Pharmaceuticals Business Overview
11.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Introduction
11.4.4 Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024)
11.4.5 Arbor Pharmaceuticals Recent Development
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Detail
11.5.2 GlaxoSmithKline plc. Business Overview
11.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Introduction
11.5.4 GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2019-2024)
11.5.5 GlaxoSmithKline plc. Recent Development
11.6 Ligand Pharmaceuticals Incorporated
11.6.1 Ligand Pharmaceuticals Incorporated Company Detail
11.6.2 Ligand Pharmaceuticals Incorporated Business Overview
11.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Introduction
11.6.4 Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2019-2024)
11.6.5 Ligand Pharmaceuticals Incorporated Recent Development
11.7 axxonis Pharma AG
11.7.1 axxonis Pharma AG Company Detail
11.7.2 axxonis Pharma AG Business Overview
11.7.3 axxonis Pharma AG Restless Legs Syndrome Introduction
11.7.4 axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2019-2024)
11.7.5 axxonis Pharma AG Recent Development
11.8 Kyowa Hakko Kirin Co.
11.8.1 Kyowa Hakko Kirin Co. Company Detail
11.8.2 Kyowa Hakko Kirin Co. Business Overview
11.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Introduction
11.8.4 Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2019-2024)
11.8.5 Kyowa Hakko Kirin Co. Recent Development
11.9 Jazz Pharmaceuticals, Inc.
11.9.1 Jazz Pharmaceuticals, Inc. Company Detail
11.9.2 Jazz Pharmaceuticals, Inc. Business Overview
11.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Introduction
11.9.4 Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2019-2024)
11.9.5 Jazz Pharmaceuticals, Inc. Recent Development
11.10 Omeros Corporation
11.10.1 Omeros Corporation Company Detail
11.10.2 Omeros Corporation Business Overview
11.10.3 Omeros Corporation Restless Legs Syndrome Introduction
11.10.4 Omeros Corporation Revenue in Restless Legs Syndrome Business (2019-2024)
11.10.5 Omeros Corporation Recent Development
11.11 Manhattan Pharmaceuticals
11.11.1 Manhattan Pharmaceuticals Company Detail
11.11.2 Manhattan Pharmaceuticals Business Overview
11.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Introduction
11.11.4 Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024)
11.11.5 Manhattan Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
